Table 1.
Comparison of patient characteristics stratified by number of NETLMs treated
| Overall | 1–5 Treated NETLMs | 6–10 Treated NETLMs | >10 Treated NETLMs | P value | |
|---|---|---|---|---|---|
| Number of operations | 188 | 73 | 54 | 61 | – |
| Median NETLMs treated (range) | 7 (1–67) | 3 (1–5) | 7.5 (6–10) | 17 (11–67) | – |
| Sex | .34 | ||||
| Male | 103 | 42 | 25 | 36 | – |
| Female | 85 | 31 | 29 | 25 | – |
| Median age (range, y) | 58 (15–80) | 60 (22–80) | 56.5 (15–79) | 58 (33–78) | .35 |
| Median follow-up (range, months) | 29.3 (0.4 – 214.8) | 39.4 (0.4 – 214.8) | 28.4 (2.1 – 207.1) | 18.8 (0.4 – 89.4) | < .01 |
| Median follow-up (reverse KM, 95% CI, months) | 39.2 (33.3 – 45.7) | 77.1 (49.6 – 117.1) | 40.4 (24.2 – 77.8) | 27.3 (15.8 – 35.4) | < .01 |
| Primary site | .26 | ||||
| SBNET | 128 | 48 | 34 | 46 | – |
| PNET | 41 | 14 | 15 | 12 | – |
| Other primary | 19 | 11 | 5 | 3 | – |
| Grade | .35 | ||||
| G1 | 72 | 34 | 17 | 21 | – |
| G2 | 97 | 31 | 30 | 36 | – |
| G3 | 15 | 6 | 5 | 4 | – |
| Lymphovascular invasion | 128 (88%) | 48 (90%) | 38 (86%) | 42 (86%) | .74 |
| Perineural invasion | 116 (83%) | 42 (82%) | 33 (77%) | 41 (89%) | .29 |
| Nonoperative treatments | – | ||||
| Hepatic artery embolization | 49 (26%) | 19 (27%) | 13 (24%) | 17 (28%) | .91 |
| Peptide receptor Radionucleotide therapy | 30 (16%) | 10 (14%) | 10 (19%) | 10 (16%) | .80 |
| Systemic therapy | 49 (26%) | 18 (26%) | 13 (24%) | 18 (30%) | .81 |
| Somatostatin analog preop | 114 (61%) | 41 (56%) | 28 (52%) | 45 (74%) | .03 |
| Somatostatin analog Postop | 180 (97%) | 66 (93%) | 54 (100%) | 60 (98%) | .09 |